AMRX

Amneal Pharmaceuticals, Inc. (AMRX) | Rumor.io

Amneal Pharmaceuticals

AMRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,725

Bullish sentiment (50-day avg)98%

Price to earnings ratio42

Market capitalization7.1B

Earnings per share0.48

Dividend yield (TTM)—

Revenue (annual)3B

Net income (annual)127.9M

Social

What share of all stock conversation is about AMRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 21

The FDA approval of Amneal Pharmaceuticals' generic lanreotide injection has led to a significant increase in the stock's price and trading volume, with a 12.96% gain in one day.
Analysts are bullish on the stock, with Barclays calling the FDA approval a "clearing event," and a high target price of $25, but some experts question the stock's valuation and whether the company's biosimilar pipeline can replace lost revenue.
The stock has reached a new 52-week high, and the company's business fundamentals, including excellent execution and strong price action, support the stock's structural uptrend.

Generated by AI

Sentiment

Of the messages about AMRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +2.04	98.31% -1.69	97.5% +6.7
Bearish	—	0% -2.04	1.69% new	2.5% -6.7

Bullish· Aug 26

$AMRX is expected to test 6.70 resistance and potentially reach the 7s, with a strong fundamental growth outlook.
Amneal Pharmaceuticals has solid fundamentals, with a 92.31% year-over-year increase in earnings per share to $0.25, beating estimates, and a 15.15% year-over-year increase in revenue to $535,075,000, also beating estimates.
The company's quarterly results and guidance suggest a strong outlook, with expected EPS of $0.70 to $0.85 and revenue of $2,100,000,000 to $2,200,000,000 in the upcoming fiscal year.

Bearish· Aug 26

$AMRX is trading at a low price-to-earnings ratio of less than 8, making it an attractive target for short sellers.
The company's successful phase 3 top-line results have been suppressed by market makers, suggesting manipulation in the market.
The stock's low price and promising pipeline make it a strange target for short selling, with some speculating that it could be a short-term swing setup.

Generated by AI

Topics

Of the messages about AMRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	92%	87.84%	78.57%
Analysts	0%	8%	8.11%	5.91%
Technical Analysis	0%	0%	4.05%	5.91%
Earnings	0%	0%	0%	7.64%
Controversies	0%	0%	0%	1.97%
Macro	0%	0%	0%	0%

Earnings· May 11

Amneal Pharmaceuticals ($AMRX) beats Q1 earnings estimates by $0.11 EPS and revenue estimates by $52.41M.
Q1 EPS of $0.20 beats consensus of $0.07, while revenue of $498.53M beats estimates by $52.41M, a 11.7% Y/Y increase.
Amneal Pharmaceuticals maintains FY20 EPS and revenue guidance despite Q1 beat, with EPS of $0.20 and revenue of $498.53M.

Announcements· Apr 22

Amneal Pharmaceuticals ($AMRX) has agreed to acquire Kashiv BioSciences for up to $1.1 billion in cash and stock, creating a global leader in biosimilars.
The acquisition is expected to generate $400-500 million in synergies and target a $300 billion biologics loss-of-exclusivity wave.
Amneal Pharmaceuticals has reported strong preliminary Q1 2026 results, beating expectations, and raised FY2026 guidance to $3.05-3.15 billion.

Generated by AI

Community

Of the messages about AMRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	51.11%	17.77%	28.91%
Newcomers	100%	48.89%	82.23%	71.09%

Regulars· Aug 8

Amneal Pharmaceuticals' ($AMRX) CREXONT (carbidopa and levodopa) extended-release capsules have been approved by the FDA for the treatment of Parkinson's disease.
The treatment's availability is expected to be launched in the US in September 2024, and it has the potential to benefit approximately one million people with Parkinson's disease living in the US.
The FDA approval is a significant advancement for Parkinson's disease management, with approximately 90,000 new cases diagnosed in the US each year.

Newcomers· Sep 21

The newcomer is focused on the potential for a 500% increase in the price of AMRX, citing a call option with a high confidence level and potential for a large return.
The newcomer is highlighting the company's recent FDA approval and the launch of a generic lanreotide injection, which could potentially disrupt the market and lead to a significant increase in revenue.
The newcomer is emphasizing the importance of considering multiple factors, such as trend strength, momentum, fundamentals, and projected trend duration, when making investment decisions, and is pointing out that some of their biggest gainers were bought at highs.

Generated by AI

News

Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says

6d agofinance.yahoo.com

Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating

7d agoInvesting.com

Oppenheimer Initiates Amneal Pharmaceuticals at Outperform With $27 Price Target

Amneal Pharmaceuticals (AMRX) has an average rating of buy and mean price target of $22, according t

7d agoYahoo Finance

Amneal: Even My Bull Case Barely Justifies $20/Share (NASDAQ:AMRX)

7d agoSeeking Alpha

Why Is Amneal (AMRX) Stock Rocketing Higher Today

8d agoYahoo Finance

Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection

8d agoYahoo Finance

Also Discussed

Investors talking about AMRX also mention

#	Name	Attention
1	Teva Pharmaceutical Industries Ltd. ADRTEVA	0%0
2	ASLN - ASLAN Pharmaceuticals Limited	——
3	KRTX - Karuna Therapeutics, Inc.	——
4	Kymera Therapeutics Inc.KYMR	0%0
5	PRTK - Paratek Pharmaceuticals, Inc.	——
6	GraniteShares 2x Long AAPL Daily ETFAAPB	0%new
7	Sanmina CorporationSANM	0%0
8	Cardinal Health Inc.CAH	0%new
9	F/m US Treasury 12 Month Bill ETFOBIL	0%0
10	Principal Investment Grade Corporate Active ETFIG	0%new

Amneal Pharmaceuticals, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a broad portfolio of essential medicines. Its current business centers on generics, injectables, biosimilars, and specialty branded pharmaceutical products, serving patients and healthcare providers across the United States and other international markets. The company operates through three main segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment spans a wide range of dosage forms and delivery systems, including oral solids, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, and transdermal therapies. The Specialty segment focuses on branded treatments for selected therapeutic areas, while AvKARE supplies pharmaceuticals, medical, and surgical products and services to governmental agencies. Headquartered in Bridgewater, New Jersey, Amneal Pharmaceuticals plays a significant role in expanding access to cost-effective and differentiated medicines within the global pharmaceutical market.

Website

Location

400 Crossing Boulevard

Bridgewater, NJ, 08807

United States

Social

What share of all stock conversation is about AMRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 21

The FDA approval of Amneal Pharmaceuticals' generic lanreotide injection has led to a significant increase in the stock's price and trading volume, with a 12.96% gain in one day.
Analysts are bullish on the stock, with Barclays calling the FDA approval a "clearing event," and a high target price of $25, but some experts question the stock's valuation and whether the company's biosimilar pipeline can replace lost revenue.
The stock has reached a new 52-week high, and the company's business fundamentals, including excellent execution and strong price action, support the stock's structural uptrend.

Generated by AI

Sentiment

Of the messages about AMRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +2.04	98.31% -1.69	97.5% +6.7
Bearish	—	0% -2.04	1.69% new	2.5% -6.7

Bullish· Aug 26

$AMRX is expected to test 6.70 resistance and potentially reach the 7s, with a strong fundamental growth outlook.
Amneal Pharmaceuticals has solid fundamentals, with a 92.31% year-over-year increase in earnings per share to $0.25, beating estimates, and a 15.15% year-over-year increase in revenue to $535,075,000, also beating estimates.
The company's quarterly results and guidance suggest a strong outlook, with expected EPS of $0.70 to $0.85 and revenue of $2,100,000,000 to $2,200,000,000 in the upcoming fiscal year.

Bearish· Aug 26

$AMRX is trading at a low price-to-earnings ratio of less than 8, making it an attractive target for short sellers.
The company's successful phase 3 top-line results have been suppressed by market makers, suggesting manipulation in the market.
The stock's low price and promising pipeline make it a strange target for short selling, with some speculating that it could be a short-term swing setup.

Generated by AI

Topics

Of the messages about AMRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	92%	87.84%	78.57%
Analysts	0%	8%	8.11%	5.91%
Technical Analysis	0%	0%	4.05%	5.91%
Earnings	0%	0%	0%	7.64%
Controversies	0%	0%	0%	1.97%
Macro	0%	0%	0%	0%

Earnings· May 11

Amneal Pharmaceuticals ($AMRX) beats Q1 earnings estimates by $0.11 EPS and revenue estimates by $52.41M.
Q1 EPS of $0.20 beats consensus of $0.07, while revenue of $498.53M beats estimates by $52.41M, a 11.7% Y/Y increase.
Amneal Pharmaceuticals maintains FY20 EPS and revenue guidance despite Q1 beat, with EPS of $0.20 and revenue of $498.53M.

Announcements· Apr 22

Amneal Pharmaceuticals ($AMRX) has agreed to acquire Kashiv BioSciences for up to $1.1 billion in cash and stock, creating a global leader in biosimilars.
The acquisition is expected to generate $400-500 million in synergies and target a $300 billion biologics loss-of-exclusivity wave.
Amneal Pharmaceuticals has reported strong preliminary Q1 2026 results, beating expectations, and raised FY2026 guidance to $3.05-3.15 billion.

Generated by AI

Community

Of the messages about AMRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	51.11%	17.77%	28.91%
Newcomers	100%	48.89%	82.23%	71.09%

Regulars· Aug 8

Amneal Pharmaceuticals' ($AMRX) CREXONT (carbidopa and levodopa) extended-release capsules have been approved by the FDA for the treatment of Parkinson's disease.
The treatment's availability is expected to be launched in the US in September 2024, and it has the potential to benefit approximately one million people with Parkinson's disease living in the US.
The FDA approval is a significant advancement for Parkinson's disease management, with approximately 90,000 new cases diagnosed in the US each year.

Newcomers· Sep 21

The newcomer is focused on the potential for a 500% increase in the price of AMRX, citing a call option with a high confidence level and potential for a large return.
The newcomer is highlighting the company's recent FDA approval and the launch of a generic lanreotide injection, which could potentially disrupt the market and lead to a significant increase in revenue.
The newcomer is emphasizing the importance of considering multiple factors, such as trend strength, momentum, fundamentals, and projected trend duration, when making investment decisions, and is pointing out that some of their biggest gainers were bought at highs.

Generated by AI

Amneal Pharmaceuticals

Social

Sep 21

Bullish· Aug 26

Bearish· Aug 26

Earnings· May 11

Announcements· Apr 22

Regulars· Aug 8

Newcomers· Sep 21

Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says

Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating

Oppenheimer Initiates Amneal Pharmaceuticals at Outperform With $27 Price Target

Amneal: Even My Bull Case Barely Justifies $20/Share (NASDAQ:AMRX)

Why Is Amneal (AMRX) Stock Rocketing Higher Today

Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection

Also Discussed

Amneal Pharmaceuticals, Inc.

Company Information

Location

Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says

Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating

Oppenheimer Initiates Amneal Pharmaceuticals at Outperform With $27 Price Target

Amneal: Even My Bull Case Barely Justifies $20/Share (NASDAQ:AMRX)

Why Is Amneal (AMRX) Stock Rocketing Higher Today

Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection

Also Discussed

Social

Sep 21

Bullish· Aug 26

Bearish· Aug 26

Earnings· May 11

Announcements· Apr 22

Regulars· Aug 8

Newcomers· Sep 21